Private Placement

After a multi-year slump, investors poured nearly $14 billion into cybersecurity in 2025, driven by AI risks and the relentless growth of cybercrime.

A biotech firm's promising concussion therapy, backed by NFL's Alex Smith, shows an 85% responder rate and now seeks public funding for its final push.

At CES 2026, an ice cream-scooping robot reveals PaXini's full-stack plan to solve embodied AI's biggest challenges with advanced tactile sensors and data.

The 2026 auto show reveals a market in flux. Hybrids are back, EVs adapt post-rebate, and the hunt for affordable cars intensifies. What's next?

Pharma giant Lilly and AI biotech BigHat are teaming up to solve a critical flaw in AI drug discovery, aiming to unlock a new generation of therapies.

Health tech firm IMVARIA, maker of an FDA-authorized AI for lung disease, has secured strategic funding from InHealth Ventures and Labcorp to expand its reach.

Backed by the LEGO family's firm, Adapture Renewables secures major U.S. Bank financing to build out its 441 MW Titanium solar portfolio in IL and AR.

Vera Therapeutics' novel IgAN drug gets FDA fast-track review, promising a new at-home treatment for a debilitating autoimmune kidney disease.

With its revolutionary Prime Editing tech showing promise, Prime Medicine faces a pivotal moment at the J.P. Morgan conference. Can it justify its new strategy?

Azitra will present its novel AI-driven skin therapies for rare diseases at Biotech Showcase, seeking crucial funding and partnerships to advance its pipeline.

As millions of solar panels near retirement, a Nevada facility gets the final go-ahead to turn a looming waste crisis into a source of valuable materials.

A new multi-target deal combines cutting-edge platforms to create next-gen cancer drugs, aiming to improve precision and patient outcomes.

A new alliance pairs Relation's 'Lab-in-the-Loop' AI with Deerfield's investment might, aiming to fast-track novel drugs for intractable diseases.

A first-in-class antibody shows a strong safety profile, de-risking development and offering a new, targeted approach for severe autoimmune diseases.

With a new CEO who has three FDA-approved drugs to his name, Catalio-backed Rhapsogen is poised to redefine autoimmune disease treatment. Here's why.

A Houston startup's breakthrough promises a carbon-negative way to make a critical military material, aiming to secure the US supply chain from pollution.

With a massive capital injection, Asante Gold is set to fast-track development at its key Ghanaian mines, aiming for a major surge in gold production.

With its rare disease drug JURVIGO® in late-stage trials, Mezzion appoints a veteran leader to navigate the path to approval and commercialization.

Launched at CES, Vibe Bot is a new physical AI device that captures and organizes meeting memory to finally solve the problem of hybrid work amnesia.

CleanSpark boosts Bitcoin output by over 10% and pivots to AI data centers, all while helping stabilize the power grid in times of extreme demand.